Bank of America Corp DE Sells 220,442 Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL)

Bank of America Corp DE trimmed its position in shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Free Report) by 82.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 46,598 shares of the company's stock after selling 220,442 shares during the quarter. Bank of America Corp DE's holdings in Autolus Therapeutics were worth $110,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Jane Street Group LLC bought a new position in shares of Autolus Therapeutics during the fourth quarter valued at about $26,000. Barclays PLC increased its stake in Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after buying an additional 10,866 shares during the last quarter. Daiwa Securities Group Inc. lifted its position in shares of Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after buying an additional 8,479 shares in the last quarter. Virtus ETF Advisers LLC boosted its stake in shares of Autolus Therapeutics by 29.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after buying an additional 6,081 shares during the last quarter. Finally, Bayesian Capital Management LP grew its holdings in shares of Autolus Therapeutics by 177.8% in the fourth quarter. Bayesian Capital Management LP now owns 65,000 shares of the company's stock valued at $153,000 after acquiring an additional 41,600 shares in the last quarter. Institutional investors own 72.83% of the company's stock.

Autolus Therapeutics Stock Performance

NASDAQ AUTL traded up $0.02 on Wednesday, hitting $2.05. 130,040 shares of the stock traded hands, compared to its average volume of 1,788,994. The business's fifty day moving average is $1.59 and its two-hundred day moving average is $1.93. Autolus Therapeutics PLC Sponsored ADR has a 12 month low of $1.11 and a 12 month high of $5.00. The firm has a market capitalization of $544.26 million, a price-to-earnings ratio of -2.32 and a beta of 1.75.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The company had revenue of $8.98 million during the quarter, compared to the consensus estimate of $1.59 million. Analysts expect that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AUTL. Wells Fargo & Company dropped their price target on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Needham & Company LLC reiterated a "buy" rating and set a $10.00 target price on shares of Autolus Therapeutics in a research note on Thursday, June 12th. Finally, Truist Financial reduced their price target on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $9.32.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.